Table 1.
Antibiotics | MICs (mg/L) | ||||
---|---|---|---|---|---|
Endotracheal secretion samples | Abdominal tissue sample | ||||
hospital day 13 | hospital day 17 | hospital day 27 |
|||
ISOLATE 1 | ISOLATE 2 | ISOLATE 3 | |||
Cefepime | > 64 | > 64 | > 64 | ||
Cefepime/zidebactam | 16 | 16 | 16 | ||
Ceftazidime | > 64 | > 64 | > 64 | ||
Ceftazidime/avibactam | > 64 | > 64 | > 64 | ||
Imipenem | > 64 | > 64 | > 64 | ||
Imipenem/relebactam | > 64 | > 64 | > 64 | ||
Ceftolozane/tazobactam | > 64 | > 64 | > 64 | ||
Piperacillin/tazobactam | > 64 | > 64 | > 64 | ||
Meropenem | > 64 | > 64 | > 64 | ||
Amikacin | > 64 | > 64 | > 64 | ||
Levofloxacin | > 64 | > 64 | > 64 | ||
Fosfomycin | > 256 | > 256 | > 256 | ||
Colistin | 0.25 | 0.25 | 0.25 | ||
Polymyxin B | 0.12 | 0.25 | 0.25 | ||
Imipenem + EDTA | 16 | 16 | 16 | ||
Ceftazidime/avibactam + EDTA | 16 | 16 | 16 |
Cefepime/zidebactam MICs were determined in 1:1 ratio;
For all the β-lactamase inhibitor based combination, inhibitor was at fixed 4 mg/L
EDTA: Ethylene diamine tetraacetic acid at fixed 200 mg/L
For fosfomycin, agar MIC method was employed by supplementing the medium with glucose-6-phosphate at 25 mg/L